RecruitingEarly Phase 1NCT06734273

Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

Sponsor

Nicholas Skertich

Enrollment

42 participants

Start Date

Mar 10, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity and Obesity-related Medical Conditions

Summary

This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mounjaro and a procedure called Sleeve Gastrectomy for people with obesity and obesity-related medical conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMounjaro

In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.

PROCEDURESleeve Gastrectomy

Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.